|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
GB8909916D0
(en)
*
|
1989-04-29 |
1989-06-14 |
Delta Biotechnology Ltd |
Polypeptides
|
|
US20040175795A1
(en)
|
1991-09-20 |
2004-09-09 |
Amgen Inc. |
Glial derived neurotrophic factor
|
|
WO1993006116A1
(en)
|
1991-09-20 |
1993-04-01 |
Syntex-Synergen Neuroscience Joint Venture |
Glial derived neurotrophic factor
|
|
US5733875A
(en)
|
1994-11-15 |
1998-03-31 |
Amgen Inc. |
Methods of using GDNF as a neuroprotective agent
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
WO1996033731A1
(en)
|
1995-04-26 |
1996-10-31 |
Regeneron Pharmaceuticals, Inc. |
Methods of using neurotrophic factors to enhance neuronal grafts
|
|
US6184200B1
(en)
|
1995-09-28 |
2001-02-06 |
Amgen Inc. |
Truncated glial cell line-derived neurotrophic factor
|
|
US5731284A
(en)
|
1995-09-28 |
1998-03-24 |
Amgen Inc. |
Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
|
|
US5641750A
(en)
|
1995-11-29 |
1997-06-24 |
Amgen Inc. |
Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US5641749A
(en)
|
1995-11-29 |
1997-06-24 |
Amgen Inc. |
Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
|
|
AU1121997A
(en)
|
1995-11-29 |
1997-06-19 |
Amgen, Inc. |
Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
|
|
US5837681A
(en)
|
1996-02-23 |
1998-11-17 |
Amgen Inc. |
Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US5929041A
(en)
|
1996-02-23 |
1999-07-27 |
Amgen Inc. |
Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
|
|
US5741778A
(en)
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US6455277B1
(en)
|
1996-04-22 |
2002-09-24 |
Amgen Inc. |
Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
|
|
US7138251B1
(en)
|
1996-04-22 |
2006-11-21 |
Amgen Inc. |
Polynucleotides encoding a neurotrophic factor receptor
|
|
JP2002505576A
(ja)
|
1997-05-30 |
2002-02-19 |
アムジエン・インコーポレーテツド |
神経栄養因子レセプター
|
|
WO2000034475A2
(en)
|
1998-12-09 |
2000-06-15 |
Amgen Inc. |
Grnf4, a gdnf-related neurotrophic factor
|
|
US7608681B2
(en)
*
|
1999-12-24 |
2009-10-27 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
WO2005003296A2
(en)
*
|
2003-01-22 |
2005-01-13 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
AU2003256613A1
(en)
|
2002-07-19 |
2004-02-09 |
Amgen Inc. |
Protein conjugates with a water-soluble biocompatible, biogradable polymer
|
|
US8946151B2
(en)
|
2003-02-24 |
2015-02-03 |
Northern Bristol N.H.S. Trust Frenchay Hospital |
Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
|
|
US8921528B2
(en)
*
|
2004-06-01 |
2014-12-30 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
|
US20060074225A1
(en)
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
US8008453B2
(en)
*
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
AU2007285763B2
(en)
*
|
2006-08-18 |
2011-12-15 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
|
CN101687933B
(zh)
*
|
2007-05-30 |
2015-11-25 |
浦项工科大学校产学协力团 |
免疫球蛋白融合蛋白
|
|
EP2152751A1
(en)
*
|
2007-05-31 |
2010-02-17 |
Genmab A/S |
Fusion or linked proteins with extended half life
|
|
WO2009070597A2
(en)
*
|
2007-11-26 |
2009-06-04 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of gdnf to the cns
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
CN103819564A
(zh)
*
|
2009-06-11 |
2014-05-28 |
安吉奥开米公司 |
用于将gdnf和bdnf递送至中枢神经系统的融合蛋白
|
|
EP2504360B1
(en)
|
2009-11-23 |
2018-08-15 |
Amgen Inc. |
Monomeric antibody fc
|
|
EP3415528B1
(en)
|
2011-04-13 |
2021-05-26 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
WO2015073727A1
(en)
*
|
2013-11-13 |
2015-05-21 |
Aequus Biopharma, Inc. |
Engineered glycoproteins and uses thereof
|
|
AU2015231170B2
(en)
*
|
2014-03-20 |
2019-10-03 |
Bristol-Myers Squibb Company |
Serum albumin-binding fibronectin type III domains
|
|
US11912750B2
(en)
|
2016-11-10 |
2024-02-27 |
Keros Therapeutics, Inc. |
GDNF fusion polypeptides and methods of use thereof
|